Equity Details
Price & Market Data
Price: $28.25
Daily Change: +$3.25 / 11.51%
Daily Range: $24.53 - $28.25
Market Cap: $1,209,670,016
Daily Volume: 142,734
Performance Metrics
1 Week: 3.60%
1 Month: -16.10%
3 Months: -16.10%
6 Months: -16.10%
1 Year: -16.10%
YTD: -23.82%
About Hemab Therapeutics Holdings, Inc. (COAG)
A complete financial picture of Hemab Therapeutics Holdings, Inc. (COAG). Current price: 28.25, daily change: +$3.25 / 11.51%. Market cap: 1,209,670,016. Performance over 1-month and 6-month periods.
Company Details
Employees: 72
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.